跳至主要内容
临床试验/NCT03467087
NCT03467087已完成不适用

Safety and Feasibility of Electrical Muscle Stimulation in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation or Chemotherapy Requiring Hospitalization

University Hospital, Saarland0 个研究点目标入组 45 人开始时间: 2016年2月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
45
主要终点
Feasibility of self administered EMS

研究概览

简要总结

Intensive chemotherapy, with or without following autologous or allogeneic stem cell transplantation (HSCT), is often the only curative treatment option for patients with haematological malignancies, leave many survivors physically and psychologically impaired because of side effects, many caused by weeks of immobilisation. Electrical muscle stimulation (EMS) is a proven training tool to improve physical performance in seniors and patients with chronic disease. The investigators therefore intend to evaluate the safety and feasibility of EMS in patients undergoing autologous HSCT, allogeneic HSCT and intensive chemotherapy. To assess feasibility all patients are asked to document training time during hospitalization in an EMS diary.

Furthermore, physical Performance will be measured using the 6-minute-walking distance (6MWD) and Short Physical Performance Battery (SPPB) as well as psychological performance using the Multidimensional Fatigue Inventory (MFI) and EORTC QLQ-C30 at the start of chemotherapy (T1) and when patients are discharged from hospital (T2).

At the time intensive chemotherapy is started and all inclusion and no exclusion criteria are met, patients will receive an EMS device with electrodes and will be instructed on how to use the device. After that, baseline tests using the above mentioned tools will be performed.

EMS will be conducted with a "Myopuls 2000" (Curatec Services GmbH, Moers, Germany) device using 13 cm x 5 cm electrodes. Electrodes are placed subsequently on both thighs and upper arms with instructions to stimulate each limb for at least 15 minutes on at least 5 days per week. Stimulation settings were as follows: 300 µs pulse width, 60 Hz frequency, 5 seconds on, 5 seconds off. The amplitude is initially set to elicit a visible muscle contraction and patients are encouraged to increase the amplitude as much as tolerated. After an initial training session, patients are to use the devices on their own and document their activities in an EMS diary.

Patients are then asked to use EMS throughout their therapy in addition to physical therapy until the day of their discharge when the initially performed tests are repeated.

The investigators hypothesis is, that EMS can be safely applied in patients undergoing intensive chemotherapy regimens and that patients are able to administer EMS by themselfs.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •18 - 80 years of age
  • •ECOG mperformance status 0-2
  • •patients undergoing chemotherapy regimens and and expected hospitalization time of > 14 days

排除标准

  • •patients with pacemakers and defibrillators
  • •patients with metallic implants close to stimulation sites
  • •skin irritations and injuries at the site of electrode placement
  • •pregnancy
  • •patient is physically or mentally unable to administer EMS by him/her -self
  • •history of ventricular arrhythmias
  • •peripheral arterial disease
  • •deep vein thrombosis in the past 3 month
  • •myocardial infarction or stroke in the past 3 month

研究组 & 干预措施

Electrical muscle stimulation

Experimental

Electrical muscle stimulation is administered on both thighs and upper arms using a Myopuls 2000D device. Pre-set training time is 30 minutes per day (15 minutes for thighs and 15 minutes for upper arms) for at least 5 days a week.

干预措施: Myopuls 2000D (Device)

结局指标

主要结局

Feasibility of self administered EMS

时间窗: At the time of discharge of every patients, after an average of 30 days

Percentage of patients able to complete at least 2/3 of the pre-set training time

Occurence of adverse events caused by EMS

时间窗: through study completion, an average of 30 days

Possible adverse events: bleeding events (defined according to the WHO Bleeding Scale ), arrhythmias, CK elevation, skin irritation

次要结局

  • Physical performance as assessed by the 6 minute walking distance(At the time of discharge of every patients, after an average of 30 days)
  • Psychological performance as assessed by the Multidimensional Fatigue Inventory(At the time of discharge of every patients, after an average of 30 days)
  • Psychological performance as assessed by the EORTC QoL 30 questionnaire(At the time of discharge of every patients, after an average of 30 days)
  • Physical performance as assessed by the Short Physical Performance Battery(At the time of discharge of every patients, after an average of 30 days)

研究者

发起方
University Hospital, Saarland
申办方类型
Other
责任方
Sponsor

相似试验

Unknown
2 期
MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System LymphomaPrimary Central Nervous System Lymphoma
NCT02399189Jun Zhu39
进行中(未招募)
1 期
High-dose chemotherapy and autologous stem cell transplant or consolidating conventional chemotherapy in primary CNS lymphoma -randomized phase III trialPrimary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors.It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of Bcell origin, accounting to the subtype diffuse large B-cell lymphoma.(DLBCL). Prognosis without treatment resembles that of systemic highgrade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.MedDRA version: 21.0Level: PTClassification code 10007953Term: Central nervous system lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2012-000620-17-ITCITY OF STUTTGART, REPRESENTED BY KLINIKUM STUTTGART250
进行中(未招募)
1 期
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy against conventional consolidating therapy with 2 cycles of conventional chemotherapy with R-DeVIC (Rituximab, Dexamthason, Etoposide, Ifosfamide, Carboplatin).Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of B-cell origin, accounting to the subtype diffuse large B-cell lymphoma. (DLBCL). Prognosis without treatment resembles that of systemic high-grade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.
EUCTR2012-000620-17-DEandeshauptstadt Stuttgart, represented by the Executive Medical Director Klinikum Stuttgart330
进行中(未招募)
1 期
In the presently planned multicentre Phase III trial the two therapies will be compared: Patients will be randomized after intensified induction treatment with 4 cycles rituximab, methotrexate, cytarabine and thiotepa (MATRix) between first-line high-dose chemotherapy against conventional consolidating therapy with 2 cycles of conventional chemotherapy with R-DeVIC (Rituximab, Dexamthason, Etoposide, Ifosfamide, Carboplatin).Primary CNS lymphoma (PCNSL) accounts for 1 to 2% of all Non-Hodgkin's lymphomas (NHL) and for 2 to 7% of all primary CNS tumors. It's incidence has increased over the past 30 years, particularly in immunocompetent individuals. Over 90% of PCNSL are lymphomas of B-cell origin, accounting to the subtype diffuse large B-cell lymphoma. (DLBCL). Prognosis without treatment resembles that of systemic high-grade NHL, and the median survival of untreated patients with PCNSL is approximately 3 months.MedDRA version: 19.0Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disorders
EUCTR2012-000620-17-NOandeshauptstadt Stuttgart, represented by Prof. Dr. J. Graf, Leitender Aerztlicher Direktor Klinikum Stuttgart346
已完成
3 期
High-dose chemotherapy and autologous stem cell transplantion or consolidating conventional chemotherapy in primary CNS lymphoma – randomized phase III trial - MATRix / IELSG43C83.3Diffuse large B-cell lymphoma
DRKS00005503Klinik für Haematologie, Onkologie und Palliativmedizin, Stuttgart Cancer Center / Tumorzentrum Eva Mayr-StihlKlinikum Stuttgart342